EritreaTuberculosis profile
Population  2016 5 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.64 (0.29–1.1) 13 (5.9–23)
Mortality (HIV+TB only) 0.075 (0.036–0.13) 1.5 (0.72–2.6)
Incidence  (includes HIV+TB) 3.7 (1.7–6.4) 74 (34–129)
Incidence (HIV+TB only) 0.22 (0.14–0.31) 4.4 (2.9–6.3)
Incidence (MDR/RR-TB)** 0.14 (0.028–0.26) 2.9 (0.57–5.2)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.23 (0.081–0.38) 1.2 (0.4–1.9) 1.4 (0.49–2.3)
Males 0.26 (0.092–0.43) 2 (0.7–3.3) 2.3 (0.79–3.7)
Total 0.49 (0.17–0.82) 3.2 (1.1–5.2) 3.7 (1.7–6.4)
TB case notifications, 2016  
Total cases notified 2 246
Total new and relapse 2 215
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 65%
          - % bacteriologically confirmed among pulmonary 57%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 61% (35–130)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.22 (0.07–0.41)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 132 6%
          - on antiretroviral therapy 128 97%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  63
(19–110)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance 5% 18% 144
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 24, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 24, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 90% 2 061
Previously treated cases, excluding relapse, registered in 2015 85% 34
HIV-positive TB cases registered in 2015 86% 122
MDR/RR-TB cases started on second-line treatment in 2014 67% 24
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
27% (24–29)
TB financing, 2017  
National TB budget (US$ millions) 4.3
Funding source: <1% domestic, 55% international, 45% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data